AutoImmune Technologies
AutoImmune Technologies
AutoImmune Technologies develops medical diagnostic tests, explores disease mechanisms, and investigates therapies for autoimmune diseases and other disorders. In addition, the Company has recently begun developing anti-viral drugs which are designed to prevent viral particles from fusing with their target cells. Many of the Company’s products are based on proprietary technologies it has licensed from Tulane University School of Medicine. Its products are based on breakthrough research discoveries, and patents covering most of the products have been awarded in the U.S. and in other countries. The Company is developing an influenza drug, a blood test to aid in the diagnosis of Lassa fever, a blood test to aid in the diagnosis of fibromyalgia, a blood test to aid in the diagnosis of systemic lupus erythematosus, Sjögren’s syndrome, juvenile rheumatoid arthritis and Grave’s disease, and a blood test to detect the presence of the pro-viral DNA of an inherited retrovirus that appears to be associated with most cases of breast cancer.